CMA incorrectly analysed evidence in Prochlorperazine decision, drugmaker says

The UK’s competition watchdog failed to analyse evidence correctly when fining pharmaceutical companies for sharing the market for an anti-nausea drug and “flippantly” accused two of the drugmakers of creating a false paper trail, the Competition Appeal Tribunal has heard.

Unlock unlimited access to all Global Competition Review content